HealthInvest Partners’s Alnylam Pharmaceuticals ALNY Stock Holding History

HealthInvest Partners’s Portfolio ALNY Stock Details ALNY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	$22.1K	Buy	+93	New	+$19.8K	0.04%	31

Other funds holding ALNY

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

HealthInvest Partners's ALNY Position: Q4 2022 in Review

HealthInvest Partners opened a new position in Alnylam Pharmaceuticals (ALNY) in Q4 2022: 93 shares worth $22.1K. The stake represents 0.04% of the portfolio and ranks #31 among its holdings.

488 funds tracked by Wall St. Rank hold ALNY as of Q4 2022.

HealthInvest Partners held 93 shares of Alnylam Pharmaceuticals worth $22.1K as of Q4 2022.
Alnylam Pharmaceuticals was a new HealthInvest Partners position in Q4 2022.
Alnylam Pharmaceuticals made up 0.04% of HealthInvest Partners's portfolio in Q4 2022, its #31 holding.
488 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q4 2022.

Based on HealthInvest Partners's 13F filing for Q4 2022, filed 14 Feb 2023.